Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer

Conditions

• Lung Cancer

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• carboplatin — DRUG
• cisplatin — DRUG
• docetaxel — DRUG
• etoposide — DRUG
• paclitaxel — DRUG
• vinblastine sulfate — DRUG
• vinorelbine tartrate — DRUG
• gene expression analysis — GENETIC
• positron emission tomography — PROCEDURE
• fludeoxyglucose F 18 — RADIATION
• radiation therapy — RADIATION

Study Details

RATIONALE: Imaging procedures, such as fludeoxyglucose F18 positron emission tomography (\^18FDG-PET), may improve the ability to detect disease progression and help doctors predict a patient's response to treatment and plan more effective treatment. PURPOSE: This phase II trial is studying how well \^18FDG-PET imaging works in detecting disease progression and determining response to treatment in patients who are undergoing chemoradiotherapy for locally advanced non-small cell lung cancer.

Key Dates

Start date

Mar 31, 2005

Status verified

Oct 2007

Primary completion

Jun 30, 2006

Study Design

Enrollment

250 participants (estimated)

Primary purpose

DIAGNOSTIC

Primary Outcome Measure

Relationship of survival to post-treatment peak standardized uptake value (SUV) as determined by the imaging institution

Locations (46)

Find similar trials in Birmingham, AL

Related Studies

• Evaluation for NCI Surgery Branch Clinical Research Protocols
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Collection of Blood From Patients With Cancer
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
• Detection of Genetic Markers of Lung Cancer
  Recruiting · University of Pittsburgh · Pittsburgh, Pennsylvania
• Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
  Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland